Immuno-Oncology

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW.

Kohei Shitara, MD, discusses 4-year survival data of chemotherapy plus nivolumab in advanced gastric/GEJ cancer or esophageal adenocarcinoma.

The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA.

Functional imaging information from 18F-FDG PET can complement data from anatomic imaging studies from CT and MRI to predict response to ICI therapy.

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.

Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

Nivolumab plus chemotherapy improved PFS and OS vs chemotherapy alone in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, according to 4-year data from the phase 3 CheckMate 649 study.

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

China’s NMPA has accepted the sNDA seeking the approval of cadonilimab plus chemotherapy for use in select patients with gastric or GEJ adenocarcinomas.

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.

A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non­–small cell lung cancer.

A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non­–small cell lung cancer.

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research.

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

The phase 3 KEYLYNK-008 trial evaluating pembrolizumab plus olaparib in patients with metastatic squamous non–small cell lung cancer will be discontinued for futility, according to an announcement from Merck.

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.

The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

Biagio Ricciuti, MD, discusses the need to improve the identification of patients with advanced non–small cell lung cancer that benefit most from immune checkpoint inhibition.